Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nitzan Hasson

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Cancer Immunology, Immunotherapy : CII|August 6, 2024
GP100 expression is variable in intensity in melanomaJacqueline E Mann, Nitzan Hasson, David G Su, et al.
The Oncologist|November 25, 2025
Survival of patients with metastatic renal cell carcinoma with or without brain metastasesNoam Savion-Gaiger, Bryden Considine, Nitzan Hasson, et al.
Journal for Immunotherapy of Cancer|September 11, 2025
Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetesLilach Aizenbud, Noam Savion Gaiger, Ana Luisa Perdigoto, et al.
Journal for Immunotherapy of Cancer|June 25, 2026
Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanomaJames William Smithy, Allison Betof, Sebastian Klobuch, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Cancer Immunology, Immunotherapy : CII|August 6, 2024
GP100 expression is variable in intensity in melanomaJacqueline E Mann, Nitzan Hasson, David G Su, et al.
The Oncologist|November 25, 2025
Survival of patients with metastatic renal cell carcinoma with or without brain metastasesNoam Savion-Gaiger, Bryden Considine, Nitzan Hasson, et al.
Journal for Immunotherapy of Cancer|September 11, 2025
Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetesLilach Aizenbud, Noam Savion Gaiger, Ana Luisa Perdigoto, et al.
Journal for Immunotherapy of Cancer|June 25, 2026
Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanomaJames William Smithy, Allison Betof, Sebastian Klobuch, et al.
Pageof 1